Pietro Bulian

4.5k total citations
88 papers, 1.7k citations indexed

About

Pietro Bulian is a scholar working on Genetics, Immunology and Pathology and Forensic Medicine. According to data from OpenAlex, Pietro Bulian has authored 88 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 51 papers in Genetics, 45 papers in Immunology and 41 papers in Pathology and Forensic Medicine. Recurrent topics in Pietro Bulian's work include Chronic Lymphocytic Leukemia Research (48 papers), Lymphoma Diagnosis and Treatment (40 papers) and Immunodeficiency and Autoimmune Disorders (22 papers). Pietro Bulian is often cited by papers focused on Chronic Lymphocytic Leukemia Research (48 papers), Lymphoma Diagnosis and Treatment (40 papers) and Immunodeficiency and Autoimmune Disorders (22 papers). Pietro Bulian collaborates with scholars based in Italy, Ukraine and United States. Pietro Bulian's co-authors include Valter Gattei, Giovanni Del Poeta, Antonella Zucchetto, Renato Zambello, Livio Trentin, Carlo Agostini, Gianpietro Semenzato, Mauro Buttarello, Riccardo Bomben and Francesca Maria Rossi and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Pietro Bulian

84 papers receiving 1.7k citations

Peers

Countries citing papers authored by Pietro Bulian

Since Specialization

Citations

This map shows the geographic impact of Pietro Bulian's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pietro Bulian with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pietro Bulian more than expected).

Fields of papers citing papers by Pietro Bulian

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pietro Bulian. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pietro Bulian. The network helps show where Pietro Bulian may publish in the future.

Co-authorship network of co-authors of Pietro Bulian

This figure shows the co-authorship network connecting the top 25 collaborators of Pietro Bulian. A scholar is included among the top collaborators of Pietro Bulian based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pietro Bulian. Pietro Bulian is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	NOTCH1-mutated chronic lymphocytic leukemia cells are characterized by a MYC-related overexpression of nucleophosmin 1 and ribosome-associated components 2017 ·Leukemia ·Federico Pozzo, Tamara Bittolo, Elena Vendramini, Riccardo Bomben, Pietro Bulian, Francesca Maria Rossi, Antonella Zucchetto, Erika Tissino, Massimo Degan, Giovanni D’Arena, Francesco Di Raimondo, Francesco Zaja, Gabriele Pozzato, Davide Rossi, Gianluca Gaïdano, Giovanni Del Poeta, Valter Gattei, Michele Dal Bo	46
2	Primary Non-Hodgkin's Lymphoma of the Vulva 2016 ·Medicine ·Nicolò Clemente, Lara Alessandrini, Maurizio Rupolo, Pietro Bulian, (unknown), Vincenzo Canzonieri, Francesco Sopracordevole	11
3	Functional and Clinical Significance of the Integrin Alpha Chain CD49d Expression in Chronic Lymphocytic Leukemia 2016 ·Current Cancer Drug Targets ·Michele Dal Bo, Erika Tissino, Dania Benedetti, (unknown), Riccardo Bomben, Giovanni Del Poeta, Gianluca Gaïdano, Francesca Maria Rossi, Pietro Bulian, Antonella Zucchetto, Valter Gattei	9
4	The B-Cell Receptor Signaling Inhibitor Molecules CD305 and CD307b Are Markers of Favorable Prognosis in Chronic Lymphocytic Leukemia with Both Mutated and Unmutated IGHV Gene Status 2016 ·Blood ·Dania Benedetti, (unknown), Erika Tissino, Michele Dal Bo, Pietro Bulian, Riccardo Bomben, Francesca Maria Rossi, Massimo Degan, Alessandro Poggi, Mahdi Shabani, Fazel Shokri, Francesco Zaja, Gabriele Pozzato, Annalisa Chiarenza, Francesco Di Raimondo, Giovanni Del Poeta, Valter Gattei, Antonella Zucchetto	2
5	IGHV gene mutational status and 17p deletion are independent molecular predictors in a comprehensive clinical-biological prognostic model for overall survival prediction in chronic lymphocytic leukemia 2012 ·Journal of Translational Medicine ·Pietro Bulian, Davide Rossi, Francesco Forconi, Giovanni Del Poeta, Francesco Bertoni, Emanuele Zucca, Marco Montillo, Gabriele Pozzato, Giovanni D’Arena, Dimitar G. Efremov, Roberto Marasca, Francesco Lauria, Gianluca Gaïdano, Valter Gattei, Luca Laurenti	21
6	Multivalent proteoglycan modulation of FGF mitogenic responses in perivascular cells 2012 ·Angiogenesis ·Sabrina Cattaruzza, Uğur Özerdem, Martin S. Denzel, Barbara Ranscht, Pietro Bulian, Ugo Cavallaro, (unknown), Alfonso Colombatti, William B. Stallcup, Roberto Perris	34
7	Prognostic impact of ZAP-70 expression in chronic lymphocytic leukemia: mean fluorescence intensity T/B ratio versus percentage of positive cells 2010 ·Journal of Translational Medicine ·Francesca Maria Rossi, Maria Ilaria Del Principe, Davide Rossi, Maria Irno Consalvo, Fabrizio Luciano, Antonella Zucchetto, Pietro Bulian, Riccardo Bomben, Michele Dal Bo, Marco Fangazio, Dania Benedetti, Massimo Degan, Gianluca Gaïdano, Giovanni Del Poeta, Valter Gattei	18
8	CD38/CD31, the CCL3 and CCL4 Chemokines, and CD49d/Vascular Cell Adhesion Molecule-1 Are Interchained by Sequential Events Sustaining Chronic Lymphocytic Leukemia Cell Survival 2009 ·Cancer Research ·Antonella Zucchetto, Dania Benedetti, Claudio Tripodo, Riccardo Bomben, Michele Dal Bo, Daniela Marconi, Fleur Bossi, Debora Lorenzon, Massimo Degan, Francesca Maria Rossi, Davide Rossi, Pietro Bulian, Vito Franco, Giovanni Del Poeta, Silvia Deaglio, Gianluca Gaïdano, Francesco Tedesco, Fabio Malavasi, Valter Gattei	118
9	Human immunodeficiency virus–associated precursor T-lymphoblastic leukemia/lymphoblastic lymphoma: report of a case and review of the literature 2009 ·Human Pathology ·Debora Lorenzon, Tiziana Perin, Pietro Bulian, Vallì De Re, Laura Caggiari, Mariagrazia Michieli, Rosa Manuele, Michele Spina, Valter Gattei, Marco Fasan, Umberto Tirelli, Vincenzo Canzonieri	0
10	Spontaneous apoptosis and proliferation detected by BCL-2 and CD71 proteins are important progression indicators within ZAP-70 negative chronic lymphocytic leukemia 2009 ·Leukemia & lymphoma ·Giovanni Del Poeta, Maria Ilaria Del Principe, Luca Maurillo, Francesca Maria Rossi, Francesco Buccisano, Emanuele Ammatuna, (unknown), Antonella Zucchetto, Gianfranco Catalano, Pietro Bulian, Antonio Bruno, Adriano Venditti, Paolo de Fabritiis, Valter Gattei, Sergio Amadori	10
11	ZAP‐70 expression in B‐cell chronic lymphocytic leukemia: Evaluation by external (isotypic) or internal (T/NK cells) controls and correlation with IgV_H mutations 2006 ·Cytometry Part B Clinical Cytometry ·Antonella Zucchetto, Riccardo Bomben, Michele Dal Bo, Paola Nanni, Pietro Bulian, Francesca Maria Rossi, Maria Ilaria Del Principe, Simone Santini, Giovanni Del Poeta, Massimo Degan, Valter Gattei	34
12	Surface-antigen expression profiling of B cell chronic lymphocytic leukemia: from the signature of specific disease subsets to the identification of markers with prognostic relevance 2006 ·Journal of Translational Medicine ·Antonella Zucchetto, Paolo Sonego, Massimo Degan, Riccardo Bomben, Michele Dal Bo, Pietro Bulian, Dania Benedetti, Maurizio Rupolo, Giovanni Del Poeta, (unknown), Valter Gattei	8
13	The New Reticulocyte Parameter (RET-Y) of the Sysmex XE 2100: Its Use in the Diagnosis and Monitoring of Posttreatment Sideropenic Anemia 2004 ·American Journal of Clinical Pathology ·Mauro Buttarello, (unknown), (unknown), (unknown), Pietro Bulian	49
14	Time-course of interleukin-2 receptor expression in interferon beta-treated multiple sclerosis patients 1998 ·Journal of Neuroimmunology ·(unknown), (unknown), Pietro Bulian, (unknown), Giovanni Biasi, B. Tavolato, Paolo Gallo	8
15	Sysmex SE-9000 Hematology Analyzer:Performance Evaluation on Leukocyte Differential Counts Using an NCCLS H20-A Protocol 1997 ·American Journal of Clinical Pathology ·Mauro Buttarello, Pietro Bulian, (unknown), Paolo Rizzotti	13
16	Tumour-infiltrating lymphocytes bear the 75 kDa tumour necrosis factor receptor 1995 ·British Journal of Cancer ·Livio Trentin, Renato Zambello, Pietro Bulian, Andrea Cerutti, (unknown), Marco A. Cassatella, Donato Nitti, M. Lise, Carlo Agostini, Gianpietro Semenzato	14
17	Functional role of IL-2 receptors on tumour-infiltrating lymphocytes 1994 ·British Journal of Cancer ·Livio Trentin, Renato Zambello, Pietro Bulian, Andrea Cerutti, A. Milani, (unknown), Donato Nitti, Carlo Agostini, Gianpietro Semenzato	12
18	Cytotoxic In vitro function in patients with metastatic renal cell carcinoma before and after alpha-2b-interferon therapy effects of activation with recombinant interleukin-2 1992 ·Cancer ·Cristina Feruglio, Renato Zambello, Livio Trentin, Pietro Bulian, (unknown), Gian Luigi Cetto, Gianpietro Semenzato	5
19	Alveolar Macrophages from Patients with AIDS and AIDS-related Complex Constitutively Synthesize and Release Tumor Necrosis Factor Alpha 1991 ·American Review of Respiratory Disease ·Carlo Agostini, Renato Zambello, Livio Trentin, Spiridione Garbisa, Paola Francia di Celle, Pietro Bulian, Maurizio Onisto, Venerino Poletti, (unknown), Enzo Raise, Robert Foà, Gianpietro Semenzato	41
20	Functional analysis of cytotoxic cells in patients with acute nonlymphoblastic leukemia in complete remission 1989 ·Cancer ·Livio Trentin, (unknown), Cristina Feruglio, Renato Zambello, M Masciarelli, Pietro Bulian, Carlo Agostini, Fabrizio Vinante, Roberta Zanotti, Gianpietro Semenzato	13

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact